GINECO
Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens
Ongoing Trials:
- Randomized trial of Avastin plus single-agent chemotherapy in platin-resistant ovarian cancer (Aurelia)
- Randomised phase III study of pazopanib versus control as maintenance therapy after first-line paclitaxel-carboplatin in ovarian cancer (Ovar 16)
- Randomised phase III of BI1120 versus placebo in combination with and maintenance therapy after first-line paclitaxel-carboplatin in ovarian cancer to replace the ICON-7 trial (AGO-OVAR-12)
- Endometrial cancer in relapse or metastatic: everolimus in monotherapy (Endorad)
- A phase I/II study of carboplatin and weekly topotecan in patients with relapsing/metastatic cervix carcinoma (HYCAR)
- A two stage trial of lenalidomide a phase II study of lenalidomide as single agent in asymptomatic ovarian cancer patients with increasing CA 125 in late relapse: followed by a phase I of lenalidomide in combination with carboplatin and liposomal pegylated doxorubicin. (REV study)
• Back
* If you are unable to view PDF files, please download a free PDF Reader from Adobe's website.